P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study

Giorgio Cocconi, Vittorio Franciosi, Anna Dodero, Alessandra Bologna, Giovanna Vasini, Vincenzo De Lisi, Beatrice Di Blasio, Guido Ceci, Roberta Camisa, Stefano Cascinu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We designed the P-CHOP regimen, which involves the addition of cisplatin (P) to the standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, and investigated its activity and its toxicities in a single institution phase II study. Twenty-two consecutive patients with untreated, aggressive, stage I-IV non-Hodgkin lymphoma were enrolled in the study. Cisplatin was administered at a dose of 40 mg/m2 on days 1 and 2, every 3 weeks; the dose and schedule of the other agents were identical to those used in the standard CHOP regimen. The complete remission (CR) rate was 86% in eligible and 80% in all the treated patients, which compares favorably with the CR rates of two recent randomized studies of CHOP versus other regimens. P-CHOP is an innovative regimen for the front-line treatment of aggressive non-Hodgkin lymphoma. It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms.

Original languageEnglish
Pages (from-to)535-542
Number of pages8
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number6
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Non-Hodgkin's Lymphoma
Cisplatin
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Appointments and Schedules
Therapeutics
Research
VAP-cyclo protocol
Rituximab

Keywords

  • Aggressive non-Hodgkin lymphoma
  • Cisplatin
  • First-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

P-CHOP : Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study. / Cocconi, Giorgio; Franciosi, Vittorio; Dodero, Anna; Bologna, Alessandra; Vasini, Giovanna; De Lisi, Vincenzo; Di Blasio, Beatrice; Ceci, Guido; Camisa, Roberta; Cascinu, Stefano.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 6, 12.2003, p. 535-542.

Research output: Contribution to journalArticle

Cocconi, Giorgio ; Franciosi, Vittorio ; Dodero, Anna ; Bologna, Alessandra ; Vasini, Giovanna ; De Lisi, Vincenzo ; Di Blasio, Beatrice ; Ceci, Guido ; Camisa, Roberta ; Cascinu, Stefano. / P-CHOP : Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2003 ; Vol. 26, No. 6. pp. 535-542.
@article{73e7bf63a92f48d2bd0c4466b2e447f6,
title = "P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study",
abstract = "We designed the P-CHOP regimen, which involves the addition of cisplatin (P) to the standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, and investigated its activity and its toxicities in a single institution phase II study. Twenty-two consecutive patients with untreated, aggressive, stage I-IV non-Hodgkin lymphoma were enrolled in the study. Cisplatin was administered at a dose of 40 mg/m2 on days 1 and 2, every 3 weeks; the dose and schedule of the other agents were identical to those used in the standard CHOP regimen. The complete remission (CR) rate was 86{\%} in eligible and 80{\%} in all the treated patients, which compares favorably with the CR rates of two recent randomized studies of CHOP versus other regimens. P-CHOP is an innovative regimen for the front-line treatment of aggressive non-Hodgkin lymphoma. It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms.",
keywords = "Aggressive non-Hodgkin lymphoma, Cisplatin, First-line chemotherapy",
author = "Giorgio Cocconi and Vittorio Franciosi and Anna Dodero and Alessandra Bologna and Giovanna Vasini and {De Lisi}, Vincenzo and {Di Blasio}, Beatrice and Guido Ceci and Roberta Camisa and Stefano Cascinu",
year = "2003",
month = "12",
doi = "10.1097/01.coc.0000037110.25789.62",
language = "English",
volume = "26",
pages = "535--542",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - P-CHOP

T2 - Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study

AU - Cocconi, Giorgio

AU - Franciosi, Vittorio

AU - Dodero, Anna

AU - Bologna, Alessandra

AU - Vasini, Giovanna

AU - De Lisi, Vincenzo

AU - Di Blasio, Beatrice

AU - Ceci, Guido

AU - Camisa, Roberta

AU - Cascinu, Stefano

PY - 2003/12

Y1 - 2003/12

N2 - We designed the P-CHOP regimen, which involves the addition of cisplatin (P) to the standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, and investigated its activity and its toxicities in a single institution phase II study. Twenty-two consecutive patients with untreated, aggressive, stage I-IV non-Hodgkin lymphoma were enrolled in the study. Cisplatin was administered at a dose of 40 mg/m2 on days 1 and 2, every 3 weeks; the dose and schedule of the other agents were identical to those used in the standard CHOP regimen. The complete remission (CR) rate was 86% in eligible and 80% in all the treated patients, which compares favorably with the CR rates of two recent randomized studies of CHOP versus other regimens. P-CHOP is an innovative regimen for the front-line treatment of aggressive non-Hodgkin lymphoma. It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms.

AB - We designed the P-CHOP regimen, which involves the addition of cisplatin (P) to the standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, and investigated its activity and its toxicities in a single institution phase II study. Twenty-two consecutive patients with untreated, aggressive, stage I-IV non-Hodgkin lymphoma were enrolled in the study. Cisplatin was administered at a dose of 40 mg/m2 on days 1 and 2, every 3 weeks; the dose and schedule of the other agents were identical to those used in the standard CHOP regimen. The complete remission (CR) rate was 86% in eligible and 80% in all the treated patients, which compares favorably with the CR rates of two recent randomized studies of CHOP versus other regimens. P-CHOP is an innovative regimen for the front-line treatment of aggressive non-Hodgkin lymphoma. It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms.

KW - Aggressive non-Hodgkin lymphoma

KW - Cisplatin

KW - First-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0348134798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348134798&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000037110.25789.62

DO - 10.1097/01.coc.0000037110.25789.62

M3 - Article

C2 - 14663368

AN - SCOPUS:0348134798

VL - 26

SP - 535

EP - 542

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -